Thought Leadership
A searchable library for all Cerner Enviza thought leadership across
multiple channels. For clinical publications please click here.
Latest
How patients with rare cancers are getting ‘doubly hit’
Rare cancers (RC) are a heterogeneous group of conditions that can be associated with psychological and physical impairments. The incidence of RC is less than six cases per 100,000 people/year1 but altogether, RC diseases account for approximately 24% of all cancer cases diagnosed, higher than any single common cancer2–4. Despite advances in treatments and more long-term survivors living with cancer as a chronic illness5 , five-year relative survival rates are still lower for patients with RCs than common cancers (47% vs. 65%)3
Blog
We need to better understand the emotional impact of cancer
A cancer diagnosis can put a huge psychological burden on patients and their caregivers. Cerner Enviza is collaborating on a research study with the National Cancer Centre Singapore (NCCS) to better understand this issue and help to advance cancer care.
Podcast
Episode 5: Let's get real - Women in Leadership
Listen to this podcast where Sepi Varon and Lulu Lee share tips on effective communication to help advance your career.
Webinar
ASCO 2022 preview webinar: Key trials with high clinical and commercial impact
Join us for a preview ASCO webinar where a panel of experts will share their perspectives on the potentially practice-changing results in breast cancer, novel approaches in Non-Hodgkin Lymphoma and Myelofibrosis, and a series of exciting MOAs in early-stage trials.
Infographic
How patients with rare cancers are getting ‘doubly hit’
Rare cancers (RC) are a heterogeneous group of conditions that can be associated with psychological and physical impairments. The incidence of RC is less than six cases per 100,000 people/year1 but altogether, RC diseases account for approximately 24% of all cancer cases diagnosed, higher than any single common cancer2–4. Despite advances in treatments and more long-term survivors living with cancer as a chronic illness5 , five-year relative survival rates are still lower for patients with RCs than common cancers (47% vs. 65%)3
Newsletter
Oncology Newsletter │November 2022
Winning in the early-stage NSCLC immunotherapy landscape and more
White Paper
How to win in the evolving early-stage NSCLC landscape
Strategic considerations to successfully adapt to the rapidly changing NSCLC global market following the introduction of checkpoint inhibitors in resectable disease (non-driver)
-
Infographic
-
Infographic
-
White Paper
-
Blog
-
Webinar
-
Podcast
-
Webinar
-
Podcast
-
Infographic
-
Infographic
Editor's Picks